News
LUMO
2.920
+4.29%
0.120
Weekly Report: what happened at LUMO last week (0415-0419)?
Weekly Report · 2d ago
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
Lumos Pharma, Inc. Is advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials. Abstracts from its Phase 2 trials will be presented at several upcoming medical meetings in the US and Europe.
Barchart · 5d ago
Weekly Report: what happened at LUMO last week (0408-0412)?
Weekly Report · 04/15 10:45
Weekly Report: what happened at LUMO last week (0401-0405)?
Weekly Report · 04/08 10:49
Weekly Report: what happened at LUMO last week (0325-0329)?
Weekly Report · 04/01 10:47
Weekly Report: what happened at LUMO last week (0318-0322)?
Weekly Report · 03/25 10:49
Lumos Pharma Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Dow Jones · 03/20 16:39
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga · 03/20 16:29
Lumos Pharma’s LUM-201 Receives ‘Buy’ Rating on Strong Market Position and Promising Trial Outcomes
TipRanks · 03/20 15:45
Weekly Report: what happened at LUMO last week (0311-0315)?
Weekly Report · 03/18 10:47
Weekly Report: what happened at LUMO last week (0304-0308)?
Weekly Report · 03/11 10:45
Lumos Pharma Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/08 14:15
Lumos Pharma Price Target Maintained With a $16.00/Share by Oppenheimer
Dow Jones · 03/08 14:15
Oppenheimer Maintains Outperform on Lumos Pharma, Maintains $16 Price Target
Benzinga · 03/08 14:04
Analysts Are Bullish on Top Healthcare Stocks: Poseida Therapeutics (PSTX), Lumos Pharma (LUMO)
TipRanks · 03/08 12:50
Lumos Pharma Price Target Maintained With a $28.00/Share by HC Wainwright & Co.
Dow Jones · 03/08 12:06
HC Wainwright & Co. Reiterates Buy on Lumos Pharma, Maintains $28 Price Target
Benzinga · 03/08 11:52
Analysts Are Bullish on Top Healthcare Stocks: Lumos Pharma (LUMO), Arcturus Therapeutics (ARCT)
TipRanks · 03/08 11:30
LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
Lumos Pharma reported earnings per share of -$1.17 for the fourth quarter of 2023. The company reported revenue of $826,000. Lumos Pharma was below the analyst estimate for EPS of $1.15. The drug company just reported results.
Investorplace · 03/08 02:54
Lumos Pharma Inc reports results for the quarter ended in December - Earnings Summary
Lumos Pharma Inc reports results for the quarter ended in December. The company reported a quarterly adjusted loss of $1.17 per share. Revenue rose 61.3% to $826.00 thousand from a year ago. Lumos Pharma shares have fallen by 5.3%.
Reuters · 03/08 00:15
More
Webull provides a variety of real-time LUMO stock news. You can receive the latest news about Lumos Pharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About LUMO
Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing its clinical program and focused on identifying, acquiring, developing, and commercializing products and new therapies for people with rare diseases. Its pipeline is focused on the development of an orally administered small molecule, LUM-201, which is a growth hormone (GH) secretagogue, also called ibutamoren, for rare endocrine disorders that require injectable recombinant human growth hormone (rhGH). LUM-201 is a tablet formulation that is intended to be administered once daily. LUM-201 stimulates GH via the GH secretagogue receptor (GHSR1a), also known as the ghrelin receptor, and also suppresses the release of somatostatin, thus providing a differentiated mechanism of action to treat some rare endocrine disorders (involving a deficiency of GH) by increasing the amplitude of endogenous, pulsatile GH secretion. Lumos Pharma Sub, Inc. (Private Lumos) is its subsidiary.